Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Si-Bone (SIBN) Long-Term Debt Repayments (2021 - 2024)

Si-Bone's quarterly Long-Term Debt Repayments came in at $36.0 million in Q4 2024, up 2.06% quarter-over-quarter from $35.3 million in Q1 2023.

Si-Bone has reported Long-Term Debt Repayments for 3 years, with the latest figure at $36.0 million in Q4 2024.

  • For the quarter ending Q4 2024, Long-Term Debt Repayments changed N/A year-over-year to $36.0 million; the trailing twelve-month figure through Dec 2024 stood at $36.0 million (up 2.06% YoY), and the FY2024 full-year result was $36.0 million, up 2.06% from the prior year.
  • Long-Term Debt Repayments for Q4 2024 stood at $36.0 million, up from $35.3 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $41.0 million in Q3 2021, with the low at $35.3 million in Q1 2023.
  • Average Long-Term Debt Repayments over 3 years is $37.4 million, with a median of $36.0 million recorded in 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Si-Bone 611.92 Mn 471.80 Mn 41.94 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 36.00 Mn
Dec 31, 2024 36.00 Mn
Mar 31, 2023 35.28 Mn
Mar 31, 2023 35.28 Mn
Sep 30, 2021 41.00 Mn
Sep 30, 2021 41.00 Mn